Differential Expression of Dipeptidyl Peptidase IV (CD26) and Thyroid Peroxidase in Neoplastic Thyroid Tissues.

Umeki, Kazumi; Tanaka, Tetsuji; Yamamoto, Ikuo; Aratake, Yatsuki; Kotani, Takuya; Sakamoto, Fujio; Noguchi, Shiro; Ohtaki, Sachiya

doi:10.1507/endocrj.43.53

Cited by 23 publications

(16 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9,16 We have reported that thyroid carcinoma expresses aberrant dipeptidyl peptidase IV (CD26/DPPIV) and that enzymatic and immunohistochemical stainings of CD26/DPPIV are useful for the pathological and cytological diagnosis of thyroid tumors. [17][18][19][20] Our observations on CD26/DPPIV overexpression in thyroid neoplasms have been supported by many researchers. [21][22][23] CD26/DPPIV is a membranebound enzyme that hydrolyzes the N-terminal-end of proline-containing peptides.…”

supporting

confidence: 63%

Diagnostic utility of galectin‐3 and CD26/DPPIV as preoperative diagnostic markers for thyroid nodules

Aratake

Umeki

Kiyoyama

et al. 2002

Diagnostic Cytopathology

Self Cite

View full text Add to dashboard Cite

The aim of this study was to search for diagnostic markers that could correctly identify thyroid nodular lesions requiring urgent surgical treatment. We investigated whether galectin-3 and dipeptidyl peptidase IV (CD26/DPPIV) could be potential markers for improving the diagnostic accuracy of conventional cytology. Seventy-nine patients with histologically proven thyroid diseases were analyzed. The immunocytochemical staining results showed galectin-3 expression in neoplastic cells of all 37 papillary carcinomas, five of six follicular carcinomas, all three anaplastic carcinomas, one of three medullary carcinomas, and two of 14 follicular adenomas. All 16 adenomatous goiters were negative for galectin-3 immunostaining. On the other hand, all 37 papillary carcinomas, all six follicular carcinomas, and one of three anaplastic carcinomas revealed CD26/DPPIV expression, whereas all three medullary carcinomas were negative. Among benign thyroid lesions, four of 14 follicular adenomas and two of 16 adenomatous goiters exhibited varying degrees of immunoreactivity for CD26/DPPIV. RT-PCR analysis demonstrated overexpression of galectin-3 and CD26/DPPIV mRNAs in all six papillary and all three follicular carcinomas analyzed, whereas the mRNA expressions of these molecules were barely or not detectable in benign thyroid lesions and normal thyroid tissues, except for one case of follicular adenoma. In conclusion, we demonstrate that galectin-3 and CD26/DPPIV were consistently coexpressed at protein and mRNA levels in differentiated thyroid carcinomas. We propose that combined immunostaining for galectin-3 and CD26/DPPIV in the preoperative evaluation of thyroid nodules may play a role in accurate cytodiagnosis.

show abstract

supporting

confidence: 63%

Diagnostic utility of galectin‐3 and CD26/DPPIV as preoperative diagnostic markers for thyroid nodules

Aratake

Umeki

Kiyoyama

et al. 2002

Diagnostic Cytopathology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Among them are dipeptidylpeptidase 4 (DPP4; refs. [19][20][21][22], a-1 antitrypsin (SERPINA1; ref. 23), galectin 3 (LGALS3; ref.…”

Section: Discussionmentioning

confidence: 99%

Gene Expression Profile of Papillary Thyroid Cancer: Sources of Variability and Diagnostic Implications

Jarząb

Wiench²,

Fujarewicz³

et al. 2005

Cancer Research

239

162

View full text Add to dashboard Cite

show abstract

“…Mutated TPO genes were found in some differentiated thyroid carcinomas (Smanik et al, 1994). Although the expression of TPO mRNA was found to be the same in cancerous and benign tissue in one study (Ohta et al, 1991), others have shown suppression of TPO gene expression (Hoang-Vu et al, 1992;Fabbro et al, 1994;Tanaka et al, 1996;Umeki et al, 1996).…”

mentioning

confidence: 97%

“…Some differences in the results of experiments using TPO murine monoclonal antibodies to detect protein expression may be due to methodological approaches (Yamashita et al, 1993;Mizukami et al, 1994;Tanaka et al, 1996;Umeki et al, 1996). However, differential immunohistochemical labelling of TPO with one monoclonal antibody (mAb#47) was proposed by De Micco et al (1991) as a marker distinguishing between benign and malignant thyroid tumours, including both PTC and FTC.…”

mentioning

confidence: 99%

Is there loss or qualitative changes in the expression of thyroid peroxidase protein in thyroid epithelial cancer?

et al. 2001

View full text Add to dashboard Cite

Summary There is disagreement concerning the expression of thyroid peroxidase (TPO) in thyroid cancer, some studies finding qualitative as well as quantitative differences compared to normal tissue. To investigate TPO protein expression and its antigenic properties, TPO was captured from a solubilizate of thyroid microsomes by a panel of murine anti-TPO monoclonal antibodies and detected with a panel of antihuman TPO IgGκ Fab. TPO protein expression in 30 samples of malignant thyroid tissue was compared with TPO from adjacent normal tissues. Virtual absence of TPO expression was observed in 8 cases. In the remaining 22 malignant thyroid tumours the TPO protein level varied considerably from normal to nearly absent when compared to normal thyroid tissue or tissues from patients with Graves' disease (range less than 0.5 to more than 12.5 µg mg -1 of protein). When expressed TPO displayed similar epitopes, to that of TPO from Graves' disease tissue. The results obtained by the TPO capturing method were confirmed by SDS-PAGE and Western blot analysis with both microsomes and their solubilizates. The present results show that in about two-thirds of differentiated thyroid carcinomas, TPO protein is expressed, albeit to a more variable extent than normal; when present, TPO in malignant tissues is immunologically normal.

show abstract

Differential Expression of Dipeptidyl Peptidase IV (CD26) and Thyroid Peroxidase in Neoplastic Thyroid Tissues.

Abstract: Abstract.This paper reports the results of research to examine the possibility of using

Cited by 23 publications

References 18 publications

Diagnostic utility of galectin‐3 and CD26/DPPIV as preoperative diagnostic markers for thyroid nodules

Diagnostic utility of galectin‐3 and CD26/DPPIV as preoperative diagnostic markers for thyroid nodules

Gene Expression Profile of Papillary Thyroid Cancer: Sources of Variability and Diagnostic Implications

Is there loss or qualitative changes in the expression of thyroid peroxidase protein in thyroid epithelial cancer?

Contact Info

Product

Resources

About